A Phase 1/2 Open-Label, Multicenter, First-in- Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH- 30643 in Adult Subjects with Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)